文献速递泌尿男性生殖肿瘤

仑伐替尼联合帕博利珠单抗治疗初治或经治转移性肾细胞癌(Study 111/KEYNOTE-146):1b/2期研究

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
PubMed 文献 · Lancet Oncol · 2021-06-15

该开放标签1b/2期研究评估仑伐替尼联合帕博利珠单抗治疗转移性肾细胞癌,主要终点为24周客观缓解率(irRECIST)。联合方案显示令人鼓舞的抗肿瘤活性和可控的安全性。

要点

  • 3级治疗相关不良事件发生率57%,最常见为高血压(21%)。
  • 联合方案或可作为转移性肾细胞癌ICI治疗后的选择。

核心结论

  • 仑伐替尼联合帕博利珠单抗在转移性肾细胞癌中显示出令人鼓舞的抗肿瘤活性和可控的安全性。

研究设计与样本

  • 开放标签1b/2期研究,纳入145例转移性肾细胞癌患者,其中143例纳入疗效分析,145例纳入安全性分析。

主要发现

  • 145例患者中82例(57%)发生3级治疗相关不良事件,10例(7%)发生4级治疗相关不良事件。
  • 最常见3级治疗相关不良事件为高血压(30例,21%)。
  • 治疗相关严重不良事件发生于36例(25%)患者,3例治疗相关死亡(上消化道出血、猝死、肺炎)。

关键数值与推荐

  • 口服仑伐替尼20 mg每日一次,联合静脉帕博利珠单抗200 mg每3周一次。
  • 主要终点为研究者评估的24周客观缓解率(irRECIST)。

临床怎么用

  • 对于转移性肾细胞癌,尤其是ICI经治后进展的患者,仑伐替尼联合帕博利珠单抗可考虑作为治疗选择。

局限性

  • 研究为1b/2期单臂设计,样本量有限,需进一步随机对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizumab and lenvatinib are active as monotherapies in RCC; thus, we aimed to evaluate the combination of lenvatinib plus pembrolizumab in these patients. METHODS: We report results of the metastatic RCC cohort from an open-label phase 1b/2 study of lenvatinib plus pembrolizumab in patients aged at least 18 years with selected solid tumours and an Eastern Cooperative Oncology Group performance status of 0-1. Oral lenvatinib at 20 mg was given once daily along with intravenous pembrolizumab at 200 mg once every 3 weeks. Patients remained on study drug treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent. Efficacy was analysed in patients with clear cell metastatic RCC receiving study drug by previous therapy grouping: treatment naive, previously treated ICI naive (previously treated with at least one line of therapy but not with an anti-PD-1 or anti-PD-L1 ICI), and ICI pretreated (ie, anti-PD-1 or anti-PD-L1) patients. Safety was analysed in all enrolled and treated patients. The primary endpoint was the objective response rate at week 24 per immune-related Response Evaluation Criteria In Solid Tumors (irRECIST) by investigator assessment. This trial is registered with ClinicalTrials.gov (NCT02501096) and with the EU Clinical Trials Register (EudraCT2017-000300-26), and is closed to new participants. FINDINGS: Between July 21, 2015, and Oct 16, 2019, 145 patients were enrolled in the study. Two patients had non-clear cell RCC and were excluded from the efficacy analysis (one in the treatment-naive group and one in the ICI-pretreated group); thus, the population evaluated for efficacy comprised 143 patients (n=22 in the treatment-naive group, n=17 in the previously treated ICI-naive group, and n=104 in the ICI-pretreated group). All 145 enrolled patients were included in the safety analysis. The median follow-up was 19·8 months (IQR 14·3-28·4). The number of patients with an objective response at week 24 by irRECIST was 16 (72·7%, 95% CI 49·8-89·3) of 22 treatment-naive patients, seven (41·2%, 18·4-67·1) of 17 previously treated ICI-naive patients, and 58 (55·8%, 45·7-65·5) of 104 ICI-pretreated patients. Of 145 patients, 82 (57%) had grade 3 treatment-related adverse events and ten (7%) had grade 4 treatment-related adverse events. The most common grade 3 treatment-related adverse event was hypertension (30 [21%] of 145 patients). Treatment-related serious adverse events occurred in 36 (25%) patients, and there were three treatment-related deaths (upper gastrointestinal haemorrhage, sudden death, and pneumonia). INTERPRETATION: Lenvatinib plus pembrolizumab showed encouraging antitumour activity and a manageable safety profile and might be an option for post-ICI treatment of metastatic RCC. FUNDING: Eisai and Merck Sharp & Dohme.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Lee CH, Shah AY, Rasco D, et al. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021. PMID: 34143969. doi:10.1016/S1470-2045(21)00241-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。